US-REGISTERED COMPANY
Skip to product information
Peptiva peptides
Research Compound Retatrutide
€153,00
Sale price
€153,00
Regular price
€180,00
FOR IN VITRO LABORATORY RESEARCH ONLY.
Not intended for personal, clinical, diagnostic or veterinary use, or for administration to humans or animals.
Laboratory dispenser format
This description applies to the dispenser-format variant, not the vial-format variant.
The dispenser is a laboratory packaging and material-dispensing format. Product identity, declared quantity and storage conditions are stated in the specification for the individual material.
Laboratory dispensing format. It is not an injection or medical device and is not intended for administration to humans or animals.
MAIN RESEARCH AREAS Research profile
Editorial map of the main themes found in the scientific literature. Bar length is not a statistical score, efficacy rating, or indication for human use.
Description and specifications
Research Compound Retatrutide is a laboratory material for analytical and in vitro work, available in 10 mg and 20 mg variants.
What is retatrutide?
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide with an attached fatty diacid chain and a molecular weight of approximately 4.7 kDa. The fatty chain enables reversible binding to albumin, which substantially extends the molecule's half-life compared with natural incretin hormones.
Research background
The molecule was developed by Eli Lilly as a continuation of work on dual incretin agonists. Retatrutide remains an investigational molecule in clinical development and is not an approved medicine.
Mechanism and scientific context
Retatrutide is a triple agonist: it activates the GIP, GLP-1 and glucagon receptors. While GLP-1 and GIP receptors participate in glucose-dependent insulin signalling, the glucagon receptor is associated with hepatic metabolism and energy expenditure. The ratio of activity across the three receptors is key to its pharmacological profile and distinguishes it from dual and single agonists.
Main research areas
- GIP, GLP-1 and glucagon receptors
- multi-receptor pharmacology
- receptor activity ratios
- half-life extension by albumin binding
Level of evidence
Large clinical trials of the reference molecule exist. They do not confirm the identity, purity or safety of this research material.
Related
See also Tirzepatide and Semaglutide.
Research use only: for laboratory, analytical and in vitro research only; not for use in humans or animals. Not a medicine. Guidance on batch documentation is available in our COA guide.
PEPTIVA PRO E-BOOK · DIGITAL EDITION
Explore the scientific context in greater depth
The expanded guide covers more than 50 compounds, mechanisms of action, levels of evidence, limitations of the available data and research regimens reported in publicly available scientific literature.
- 50+ compounds covered in detail
- Preclinical and clinical data clearly distinguished
- Experimental approaches described in scientific literature
- COA, purity and documentation
Educational content is not medical advice, a recommendation for self-administration or instructions for using products sold in this store.
COA on request
To enquire about a certificate of analysis (COA), send the material name, requested variant and LOT / batch number if available. Documents are not published on this page.
Request a COA by emailThe button opens your email app with a prepared enquiry. You send the message yourself. peptivapeptides@protonmail.com
A COA applies to a specific batch and documents the analytical parameters tested for that batch. The product is intended strictly for laboratory, analytical and in vitro research.